丙型肝炎病毒基因6型感染的流行病学和治疗进展

doi:10.3969/j.issn.1672-5069.2016.04.033

Abstract

Su Minghua, Jiang Jianning. Hepatitis B virus genotype 6:Epidemiology and treatment of patients[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2016, 19(4): 497-499.

[1] Mohd Hanafiah K,Groeger J,Flaxman AD,et al. Glodal epidemiology of hepatitis C virus infection:new estimates of age-specific antibody to HCV seroprevalence.Hepatology,2013,57（4）:1333-1342.
[2] Lavanchy D. The global burden of hepatitis C. Liver Int,2009,29 （Suppl 1）:74-81.
[3] WHO. Guidelines for the screening,care and treatment of persons with hepatitis C infection. Languages,2014,124.
[4] Chen CJ,Yu MF,Liaw YF.Epidemiological characteristics and risk factors of hepatocellular carcinoma.J Gastroenterol Hepatol,1998,12（9）:S294-308.
[5] 陈圆生,李黎,崔富强,等. 中国丙型肝炎血清流行病学研究. 中华流行病学杂志,2011,32（9）:888-891.
[6] Smmonds P,Bukh J,Combet C,et al.Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes.Hepatology,2005,42（4）:962-973.
[7] Mellor J,Holmes EC,Jarvis LM,et al. Investigation of the pattern of hepatitis C virus sequence diversity in different geographical regions ：implications for virus classification.The International HCV collaborative study Grroup.J Gen Virol,1995,76,（Pt 10）:2493-2507.
[8] Alter MJ. Epidemiology of hepatitis C virus infection. World J Gastroenterol,2007,13（17）:2436-2441.
[9] Chao DT,Abe K,Nguyen MH. Syestematic review:epidemiology of hepatitis C genotype 6 and its management.Aliment Pharmacol Ther,2011,34（3）:286-296.
[10] Nguyen MH,Keeffe EB.Prevalence and treatment of hepatitis C virus genotypes 4,5 and 6.Clin Gastroenterol Hepatol,2005,3（Suppl 2）:S97-101.
[11] Vutien P,N guyen NH,Trinh HN,et al. Similar treatment response to peginterferon and ribavirin in Asian and Caucasian patients with chronic hepatitis C. Am J Gastroenterol,2010,105:1110-1115.
[12] Chen YD,Liu MY,Yu WL,et al. Hepatitis C virus infections and genotypes in China. Hepatobiliary Pancreat Dis Int,2002,1（2）:194-201.
[13] 夏文杰,叶欣,付涌水,等.广州地区人类白细胞抗原-Ⅰ类与丙型肝炎病毒6a型感染相关性的研究.中国免疫学杂志,2011,27（4）：330-334.
[14] Lu L,Nakano T,He YL,et al. Hepatitis C virus genotype distribution in China:predominance of closely related subtype 1b isolates and existence of new genotype 6 variants. J Med Virol,2005,75（4）:538-549.
[15] 唐维,苏明华,江建宁,等. 广西地区丙型肝炎病毒的基因型分布与流行病学特征.世界华人消化杂志,2014,22（9）:1300-1306.
[16] Yan ZH,Fan K,Wang YM,et al. Changing pattern of clinical epidemiology on hepatitis C virus infection in southwest China. Hepat Mon,2012,12（3）:196-204.
[17] Prati D. Transmission of hepatitis C virus by blood transfusions and other medical procedures:a global review. J Hepatol, 2006,45（4）:607-616.
[18] Seto WK,Lai CL,Fung J,et al. Natural history of chronic hepatitis C:genotype 1 versus genotype 6. J Hepatol,2010,53（3）: 444-448.
[19] Pham DA,Leuangwutiwong P,Jittmittraphap A,et al. High prevalence of hepatitis C virus genotype 6 in Vietnam. Asian Pac J Allergy Immunol,2009,27（2-3）:153-160.
[20] Seto WK,Lai CL,Fung J,et al. Natural history of chronic hepatitis C:genotype 1 versus genotype 6. J Hepatol,2010,53:444-448.
[21] 叶汉深, 许茹,王敏,等. 广州地区无偿献血人群HCV的基因分型研究. 南方医科大学学报,2010,12:2655-2657.
[22] 戎霞,郑英,熊华平,等. 广东地区临床患者和献血者HCV感染者HCV基因分型比较. 中国输血杂志,2014,27（6）：593-596.
[23] Wong DA,Tong LK,Lim W. High prevalence of hepatitis C virus genotype 6 among certain risk groups in Hong Kong. Eur J Epidemiol,1998,14:421-426.
[24] Zhou DX,Tang JW,Chu IM,et al. Hepatitis C virus genotype distribution among intravenous drug user and the general population in Hong Kong. J Med Virol,2006,78:574-581.
[25] 毛青. 中国HCV基因型分布模式变迁及HCV_6型的RGT策略. 全国病毒性肝炎慢性化、重症化基础与临床研究进展学术会议,重庆,2014:123.
[26] 韦智,苏明华,江建宁,等. 广西地区丙型肝炎病毒基因6型的流行特征及治疗分析. 中华传染病杂志,2015,33（7）：409-414.
[27] Pybus OG,Barnes E,Taggart R,et al. Genetic history of hepatitis C virus in East Asia. J Virol,2009,83:1071-1082.
[28] 洪国祜,谭朝霞,郭艳,等. 中国西南地区丙型肝炎病毒6a亚型病毒株的传播速率. 中华肝脏病杂志,2011,19:502-505.
[29] Rao HY,Wei L,Carlos J,et al. Distribution and clinical correlates of viral and host genotypes in Chinese patients with chronic hepatitis C virus infection. J Gastroenterol Hepatol,2014,29:545-553.
[30] Akkarathamrongsin S,Praianantathavorn K,Hacharoen N,et al. Geographic distribution of hepatitis C virus genotype 6 subtypes in Thailand. J Med Virol,2010,82:257-262.
[31] Wang Y,Xia X,Li C,et al. A new HCV genotype 6 subtype designated 6v was confirmed with three complete genome sequences. J Clin Virol,2009,44:195-199.
[32] Li C,Lu L,Zhang X,et al. Entire genome sequences of two new HCV subtypes,6r and 6s,and characterization of unique HVR1 variation patterns within genotype 6. J Viral Hepat,2009,16:406-417.
[33] Yang RF, Cong X,Du SC,et al. Performance comparison of the versant HCV genotype 2.0 assay（LiPA） and the Abbott realtime HCV genotype II assay for detecting hepatitis C virus genotype 6. J Clin Microbiol,2014,52:3685-3692.
[34] European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2015. J Hepatol,2015,63（1）:199-236.
[35] Scott JD,Gretch DR. Molecular diagnostics of hepatitis C virus infection:a systematic review. JAMA,2007,297:724-732.
[36] 陈新月,尚佳,杨瑞锋,等. 难治性慢性丙型肝炎初治患者优化治疗后的病毒学应答率研究.中华肝脏病杂志,2015,23（6）：412-417.
[37] Tong W,Zhu J,Luo N,et al. Response to pegylated interferon plus ribavirin in patients with hepatitis C virus genotype 6a infection from Guangdong and Guangxi province of China. Gastroenterol Res Pract,2016,2016:5397407.
[38] 何长龙,吴全新,况雪梅,等. 聚乙二醇干扰素联合利巴韦林治疗HCV 6 型感染者的临床疗效回顾性观察研究.第三军医大学学报,2015,37（12）：1252-1255.
[39] Nguyen NH,McCormack SA,Yee BE,et al. Meta-analysis of patients with hepatitis C virus genotype 6:48 weeks with pegylated interferon and ribavirin is superior to 24 weeks. Hepatol Int,2014,8（4）:540-549.
[40] Lai CL,Wong VW,Yuen MF,et al. Sofosbuvir plus ribavirin for the treatment of patients with chronic genotype 1 or 6 hepatitis C virus infection in Hong Kong. Aliment Pharmacol Ther,2016,43（1）:96-101.
[41] Everson GT,Towner WJ,Davis MN,et al. Sofosbuvir with velpatasvir in treatment-naive noncirrhotic patients with genotype 1 to 6 hepatitis C virus infection:A randomized trial. Ann Intern Med,2015,163（11）:818-826.

Hepatitis B virus genotype 6:Epidemiology and treatment of patients

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Zhang Rui, Wang Jian, Chen Shiyao.. Mechanism of portal vein thrombosis in cirrhotic patients with portal hypertension and the treatment [J]. Journal of Practical Hepatology, 2019, 22(6): 930-933.
[2]	Liang Jubo, Miao Qi, Ma Xiong.. Diagnosis and treatment of cholangiocytic cholestasis [J]. Journal of Practical Hepatology, 2019, 22(6): 941-943.
[3]	Gao Zhiliang, Zhu Xiang. How to achieve the clinical cure of hepatitis B [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(3): 305-308.
[4]	Wang Xiaoxiao, Chen Xinyue. Therapeutic strategy for serum HBsAg clearance in suitable population of chronic hepatitis B [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(3): 309-312.
[5]	Liu Li，Li Junyi，Du Yingrong. Efficacy and safety of sofosbuvir/daclatasvir in the treatment of patients with chronic hepatitis C and hepatitis C cirrhosis:An real-world study [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(3): 361-364.
[6]	Guideline for diagnosis, treatment of liver failure. [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 164-171.
[7]	Zhao Xiaofei, Lin Dongdong, Li Ning, Zang Yunjin, Guo Qingliang, Wu Juanshan. Application of warfarin in dealing with portal vein thrombosis in patients with liver cirrhosis after splenectomy and devascularization [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 240-243.
[8]	Zhong Yan, Su Shuting, Mi Yuqiang.. Treatment of patients with nonalcoholic fatty liver disease [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(1): 145-148.
[9]	Pu Yonglan, Chen Yuanwen, Fan Jiangao.. Gluten intestinal disease and nonalcoholic fatty liver: One case report [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(6): 981-982.
[10]	Li Yue, Ding Huiguo.. Current diagnosis and treatment of chylous ascites [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(5): 665-668.
[11]	Cao Fenghua, Jing Jisheng, Zhao Wei, et al.. Clinical efficacy and safety of large dose of domestic interferon-α2b and ribavirin in the treatment of patients with chronic hepatitis C [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(5): 729-732.
[12]	ZhangLining, Liu Zhigang, GaoCaixia, et al.. Application of dietary intervention with authorized education in patients with hepatitis B virus associated glomerulonephritis [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(5): 799-800.
[13]	Cao Haixia, Fan Jiangao. Brief introduction of ESPGHAN recommendation for the diagnosis and treatment of children with Wilson's disease [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(4): 502-504.
[14]	Wang Ping, Zhou Xiaojia, Liu Xinhua. Application of video-based health education in patients with hepatitis B virus associated glomerulonephritis [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(3): 451-452.
[15]	Weng Yerui, Fu Aizhen. Investigation of milk HBV DNA in pregnant women with chronic HBV infection [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(3): 457-458.